The disclosed subject matter provides for genetically modified cells, e.g., fungal cells, that autonomously generates and/or secretes one or more therapeutic molecules, e.g., therapeutic peptides, therapeutic proteins or small therapeutic molecules, in situ. In certain embodiments, the present disclosure provides genetically-engineered fungal cells that generate and secrete tetracycline and analogues thereof.

The disclosed subject matter provides for genetically modified cells, e.g., fungal cells, that autonomously generates and/or secretes one or more therapeutic molecules, e.g., therapeutic peptides, therapeutic proteins or small therapeutic molecules, in situ. In certain embodiments, the present disclosure provides genetically-engineered fungal cells that generate and secrete tetracycline and analogues thereof.

A method for improving the production of Streptomyces polyketide compounds is provided. The method greatly improves the capability of the Streptomyces polyketide compounds by strengthening a triacylglycerol decomposition pathway in Streptomyces during the stationary phase. A method for switching the primary metabolism of Streptomyces to the secondary metabolism, Streptomyces producing polyketide compounds, and use thereof are also provided.

The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.

The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.

The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.

The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.

The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.

An antibiotic FIIRV 104/18 complex comprising factors F793, F795, F797, F813 and F683, of formula (I), wherein R represents a glycosidic radical as defined in the specification, the isolated individual factors, a method for their production by cultivation of Dactylosporangium FIIRV sp. 104/18 DSM 32068 under aerobic conditions, and pharmaceutical formulations containing them as active ingredient and their use in the treatment of bacterial infections, caused by bacteria of at least one of the genera Enterococci, Streptococci, Staphylococci and Moraxella, including bacteria of multi resistant strains, in particular Staphylococcus spp., Streptococcus spp, and Enterococcus spp. resistant to methicillin and/or vancomycin.

##STR00001##

An antibiotic FIIRV 104/18 complex comprising factors F793, F795, F797, F813 and F683, of formula (I), wherein R represents a glycosidic radical as defined in the specification, the isolated individual factors, a method for their production by cultivation of Dactylosporangium FIIRV sp. 104/18 DSM 32068 under aerobic conditions, and pharmaceutical formulations containing them as active ingredient and their use in the treatment of bacterial infections, caused by bacteria of at least one of the genera Enterococci, Streptococci, Staphylococci and Moraxella, including bacteria of multi resistant strains, in particular Staphylococcus spp., Streptococcus spp, and Enterococcus spp. resistant to methicillin and/or vancomycin.

##STR00001##